Regorafenib has improved the survival of patients with refractory metastatic colorectal cancer (mCRC), yet the mechanisms of inherited or acquired resistance are not well understood. A total of 50 patients with refractory mCRC were enrolled.
| INTRODUC TI ON
Regorafenib, an oral multikinase inhibitor, blocks the activity of several protein kinases, including v-raf murine sarcoma viral oncogene homolog B1 (BRAF), 1 and improves the progression-free survival (PFS) and overall survival (OS) of chemorefractory metastatic colorectal cancer (mCRC) patients. 1, 2 A retrospective exploratory analysis of the pivotal phase III CORRECT trial proposed BEAMing analysis of circulating DNA as a potential biomarker and viable approach to obtain real-time tumor-associated genotypic information in mCRC patients treated with regorafenib. Nonetheless, there are currently no validated predictive or prognostic biomarkers of regorafenib efficacy.
Circulating tumor cells (CTCs) are shed from the primary tumor, migrate to sites of metastases, and serve as a noninvasive means of monitoring the dynamic alterations driving treatment efficacy and disease progression. The most widely studied CTC detection methods are based on immunomagnetic enrichment with antiepithelial cell adhesion molecule (EpCAM) Abs and subsequent immunological identification with anticytokeratin (anti-CK). The CellSearch system is one such method and is the only FDA-approved assay for the enumeration of CTCs in peripheral blood. [3] [4] [5] In a study by Cohen et al using CellSearch, the presence of 3 or more CTCs at baseline and follow-up was an independent prognostic marker of inferior survival in mCRC patients. [5] [6] [7] However, it is unclear whether CTC enumeration at baseline and over time is predictive or prognostic in mCRC patients specifically treated with regorafenib.
In addition to enumeration, protein expression and molecular profiling of CTCs might serve as more refined biomarkers and help inform a more personalized treatment approach. Under the pressure imposed by chemotherapy and mAbs, clonal selection and genomic instability emerge and provoke eventual treatment resistance. The ability to characterize such intratumoral heterogeneity could help to identify novel predictive and prognostic biomarkers and improve treatment decision-making. To this end, our group has previously examined the prognostic role of epithelial-mesenchymal transition (EMT) gene (PI3K, Akt-2, and Twist1) expression within CTCs of patients with mCRC (Ning Y et al). 8 In this study, we examined the ability of CTC enumeration and molecular characterization, using mRNA levels of epithelial (EGFR, EpCAM, and CEA) and EMT (PI3K, Akt-2, and Twist1) markers, to predict outcomes and identify potential molecular escape mechanisms in mCRC patients undergoing regorafenib therapy.
| MATERIAL S AND ME THODS

| Study design and patient population
This was a retrospective analysis of a prospective single-arm study examining the efficacy and toxicity of regorafenib in patients with refractory mCRC undertaken at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Eligible patients were 18 years or older with histologically confirmed mCRC, who had progressed or were intolerant to standard therapy (including a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and an antiepidermal growth factor receptor [EGFR] agent if indicated), and were subsequently treated with regorafenib at a dose of 160 mg orally daily for 21 days of every 28-day cycle. Treatment was continued until the development of intolerable toxicities or disease progression. Standard inclusion criteria applied, including ECOG performance status of 0 or 1, presence of measurable disease, life expectancy of at least 3 months, and adequate organ function.
Between March 2013 and December 2014, a total of 62 patients were enrolled, of which 50 met inclusion/exclusion criteria and had sufficient blood samples for analysis. Study protocols were approved by the Institutional Review Board at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. All patients provided written informed consent for the evaluation of molecular correlates.
| Isolation and enumeration of CTCs
Circulating tumor cell enumeration was carried out at baseline prior to initiation of regorafenib, day 21 after initiation of therapy, and at the time of treatment intolerance or progression of disease (PD) using the CellSearch system. A total of 7.5 mL whole blood was collected on a CellSave Preservative Tube, and the CellSearch Circulating Tumor Cell Kit (Veridex) was applied for CTC enrichment and enumeration. Immunomagnetic enrichment was undertaken using anti-EpCAM ferrofluid.
Enriched cells were then fluorescently stained with the nucleic acid dye DAPI and labeled with mAbs specific for epithelial cells (anti-CK8, 18, and 19) and leukocytes (anti-CD45). A CTC was defined as an EpCAM, isolated, intact, round to oval cell, with a visible nucleus (DAPI-positive), positive staining for CK, and negative staining for CD45. Results of CTC enumeration were then expressed as the number of cells per 7.5 mL blood. 9
| Gene expression analysis using quantitative RT-PCR and multiplex PCR
The mRNA expression of epithelial (EGFR, EpCAM, and CEA) and EMT (PI3K-α, Akt-2 and, TWIST1) markers in the enriched CTC cartridges after counting the CTC number using the CellSearch system was measured using the HotStarTaq Master Mix (#203443; Qiagen), a thermocycler, and the Agilent 2100 Bioanalyzer on a DNA LabChip (Agilent Technologies).
Primers for epithelial (EGFR, EpCAM, and CEA) and EMT (PI3K-α, Akt-2, and TWIST1) markers were provided by AdnaGen. The analysis of tumor cell-derived mRNA was carried out by quantitative RT-PCR for the following transcripts: EGFR, EpCAM, CEA, PI3K-α, Akt-2, and TWIST1. AdnaTest ColonCancerDetect and AdnaTest EMT-2/ StemCell Detect kits (AdnaGen), containing oligo(dT) 25 -coated beads, were used to isolate mRNA from tumor cells in the enriched CTC cartridges of CellSearch system. PrimerMix ColonDetect was first used to amplify 3 genes (EGFR, EpCAM, and CEA) and 1 control gene (Actin).
PrimerMix EMT-2/StemCell Detect was used to amplify 3 EMTrelated genes (PI3K-α, Akt-2, and TWIST1) and 1 control gene (Actin).
Visualization of PCR fragments was carried out with the Agilent 2100 Bioanalyzer, with a limit of detection of 0.01 ng/μL or more.
| Statistical analysis
The primary outcome measure was PFS, defined as the date of randomization to the date of first documented disease progression or death from any cause. If disease progression or death was not ob- 
| RE SULTS
| Patient and tumor characteristics
Clinicopathologic characteristics are presented in Table 1 . The median follow-up time was 180 days. The median PFS and OS were 69 days and 192 days, respectively. Six patients were deemed not evaluable; 2 patients had rapid disease progression, and 4 patients had adverse events. Associations between baseline characteristics and clinical outcomes were examined using the log-rank test in univariate analysis. Using the Cox regression model in a multivariable model, the presence of liver metastases, metastases to other organs, and KRAS mutation status were significantly associated with PFS and OS.
| Clinical outcomes by CTC count and gene expression in patients receiving regorafenib
The distribution of CTC count and CTC gene expression at baseline and day 21 is outlined in Associations between CTC count and outcomes are analyzed ( (Table 3) . Additionally, patients with less than 3 CTCs at baseline and day 21 had a significantly higher tumor response rate compared to those with 3 or more CTCs (Fisher's exact test, P = .007 and P = .03, respectively) ( Table 3) .
We then examined associations between CTC gene expression levels and outcomes. We used the optimal cut-off value method as previously described. [10] [11] [12] The cut-off value of 0.05 for EGFR expression at baseline was chosen based on the maximum χ 2 approach.
Patients with baseline CTC EGFR levels 0.05 or higher had a shorter PFS, compared to those with lower levels, both in univariable (HR 3.20, 95% CI, 1.16-8.80, P = .007) and multivariable (HR 4.26, 95%
CI, 1.41-11.24, P = .007) analyses. All 5 patients with increased baseline CTC EGFR expression had disease progression as their best response. No significant associations were seen with the other markers that were analyzed (Table 3 ).
| Changes in CTC count and CTC gene expression at day 21
Next, we assessed CTC count and CTC gene expression levels at day 21 and at the time of disease progression as compared to baseline.
Circulating tumor cell EGFR expression was significantly increased at day 21 and/or PD (P = .004) in 64% of patients (Table 4 ). More specifically, CTC EGFR expression was significantly increased at PD compared to baseline (P = .041) in 48% of patients. No significant associations were seen with the other genes that were analyzed.
| Associations between changes in CTC EGFR and EMT marker expression
We then hypothesized that increased CTC EGFR expression could result in an increase in the expression of CTC EMT markers. 13 However, there were no significant associations between changes in CTC EGFR and EMT marker gene expression.
| D ISCUSS I ON
Our study is the first to show that CTC enumeration and mRNA gene expression levels could be useful markers of regorafenib efficacy in mCRC patients. Specifically, we found the presence of 3 or more CTCs at baseline and day 21 to be an independent prognostic factor for inferior survival. Moreover, upregulation of CTC EGFR expression induced by regorafenib was associated with disease progression.
Regorafenib blocks both WT and mutant BRAF (V600E) signaling. Preclinical studies have previously indicated that BRAF 
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inhibition causes feedback activation of EGFR signaling and increased EGFR expression, allowing for ongoing tumor cell proliferation. 14 In previous studies, tumor tissue EGFR expression has been shown to be a negative prognostic marker. 15 Our data further support these findings, suggesting that regorafenib therapy could increase EGFR expression and signaling to an extent that leads to molecular escape and treatment resistance. Patients with baseline CTC EGFR levels 0.05 or higher had a shorter PFS and had disease progression at the time of their first radiographic evaluation.
Although It has been reported that CTCs often exist in a state of EMT or could coexpress both epithelial and mesenchymal markers. During the EMT, epithelial cells downregulate epithelial-related genes, acquire mesenchymal gene expression, and undergo major changes in their cytoskeleton that result in loss of cell-cell contact and cell polarity, leading to increased motility and invasiveness. 19 Here, we investigated the expression of CTC EMT markers, including TWIST1, Akt2,
and PI3Kα, as well as associations between CTC EGFR and EMT gene expression, and found a nonsignificant trend towards an inverse association. The lack of a significant association could reflect challenges associated with CTC characterization using the CellSearch technique,
including the presence of an excess of leukocytes, which express EMT marker genes, in CTC-enriched blood fractions.
Certain limitations of our study should be acknowledged. Our data are limited by the small sample size and are only exploratory.
The lack of a control group of patients not receiving regorafenib preclude any conclusions that can be drawn regarding the use of CTC count or associated EGFR expression as predictive markers.
In summary, we identified CTC count as a prognostic marker in mCRC patients treated with regorafenib. Circulating tumor cell EGFR expression was significantly increased with regorafenib at the time of disease progression, suggesting this to be a mode of resistance and lending further mechanistic evidence for the synergistic effects seen with regorafenib and anti-EGFR mAbs. 20 Our findings warrant further investigation and, if replicated in future investigations, could inform the selection of mCRC patients best suited for regorafenib in the chemorefractory setting.
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